MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients

Angelo Gámez-Pozo; Luis M. Antón-Aparicio; Cristina Bayona; Pablo Borrega; María I. Gallegos Sancho; Rocío García-Domínguez; Teresa de Portugal; Manuel Ramos-Vázquez; Ramón Pérez-Carrión; María V. Bolós; Rosario Madero; Iker Sánchez-Navarro; Juan A. Fresno Vara; Enrique Espinosa Arranz

doi:10.1593/neo.12734

MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients

Neoplasia ◽

10.1593/neo.12734 ◽

2012 ◽

Vol 14 (12) ◽

pp. 1144-IN14 ◽

Cited By ~ 50

Author(s):

Angelo Gámez-Pozo ◽

Luis M. Antón-Aparicio ◽

Cristina Bayona ◽

Pablo Borrega ◽

María I. Gallegos Sancho ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Peripheral Blood ◽

Expression Profiling ◽

Renal Cell ◽

Microrna Expression ◽

Advanced Renal Cell Carcinoma ◽

First Line ◽

Blood Samples

Download Full-text

Outcomes of Advanced Renal Cell Carcinoma Patients (Arcc) Treated with Mammalian Target of Rapamycin Inhibitor (Mtori) Therapy Following First-Line Pazopanib (Paz) in a Us Community Oncology Setting

Annals of Oncology ◽

10.1093/annonc/mdu337.40 ◽

2014 ◽

Vol 25 ◽

pp. iv295

Author(s):

T. Hutson ◽

M.D. Hackshaw ◽

N. Vogelzang ◽

D. Bhowmik ◽

M. Yap ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Advanced Renal Cell Carcinoma ◽

First Line ◽

Community Oncology

Download Full-text

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdz249.052 ◽

2019 ◽

Vol 30 ◽

pp. v386-v387

Author(s):

M. Uemura ◽

Y. Tomita ◽

H. Miyake ◽

S. Hatakeyama ◽

H.-O. Kanayama ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Subgroup Analysis ◽

Renal Cell ◽

Phase Iii ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70266-2 ◽

2011 ◽

Vol 12 (12) ◽

pp. 1143-1150 ◽

Cited By ~ 178

Author(s):

Jesus Garcia-Donas ◽

Emilio Esteban ◽

Luis Javier Leandro-García ◽

Daniel E Castellano ◽

Aranzazu González del Alba ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Single Nucleotide Polymorphism ◽

Prospective Study ◽

Cell Carcinoma ◽

Renal Cell ◽

Toxic Effects ◽

Advanced Renal Cell Carcinoma ◽

Nucleotide Polymorphism ◽

First Line ◽

Single Nucleotide

Download Full-text

First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2015.1058359 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1915-1927 ◽

Cited By ~ 15

Author(s):

James Larkin ◽

Abby Paine ◽

Grace Foley ◽

Stephen Mitchell ◽

Connie Chen

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00693-8 ◽

2022 ◽

Author(s):

David Cella ◽

Robert J Motzer ◽

Cristina Suarez ◽

Steven I Blum ◽

Flavia Ejzykowicz ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Patient Reported Outcomes ◽

Advanced Renal Cell Carcinoma ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Patient Reported

Download Full-text

The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study

International Journal of Clinical Oncology ◽

10.1007/s10147-018-1361-9 ◽

2018 ◽

Vol 24 (4) ◽

pp. 411-419 ◽

Cited By ~ 2

Author(s):

Aristotelis Bamias ◽

Vasilios Karavasilis ◽

Nikolaos Gavalas ◽

Kimon Tzannis ◽

Epaminontas Samantas ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

First Line ◽

Anti Vegf

Download Full-text

PCASE1 UTILIZING EVIDENCE FROM DIFFERENT LEVELS IN THE REIMBURSEMENT PROCESS OF NEW MEDICAL TECHNOLOGIES-ADVANCED RENAL CELL CARCINOMA FIRST LINE THERAPY IN POLAND 2008-2009

Value in Health ◽

10.1016/s1098-3015(10)73062-x ◽

2010 ◽

Vol 13 (3) ◽

pp. A217

Author(s):

W Matusewicz ◽

J Baran ◽

MM Farkowski

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

First Line ◽

Medical Technologies ◽

First Line Therapy ◽

Line Therapy ◽

Different Levels

Download Full-text

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

British Journal of Cancer ◽

10.1038/bjc.2012.501 ◽

2012 ◽

Vol 108 (5) ◽

pp. 1126-1132 ◽

Cited By ~ 48

Author(s):

M Scartozzi ◽

M Bianconi ◽

L Faloppi ◽

C Loretelli ◽

A Bittoni ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Clinical Outcome ◽

Cell Carcinoma ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

First Line

Download Full-text

Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma

Current Medical Research and Opinion ◽

10.1080/03007995.2020.1799771 ◽

2020 ◽

Vol 36 (9) ◽

pp. 1507-1517

Author(s):

Arielle G. Bensimon ◽

Yichen Zhong ◽

Umang Swami ◽

Allison Briggs ◽

Joshua Young ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cost Effectiveness ◽

Cell Carcinoma ◽

Renal Cell ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

The peripheral blood inflammatory markers may predict response to nivolumab for advanced renal cell carcinoma

European Urology Supplements ◽

10.1016/s1569-9056(19)31518-0 ◽

2019 ◽

Vol 18 (1) ◽

pp. e2094-e2095

Author(s):

D. Ikarashi ◽

R. Kato ◽

Y. Kato ◽

M. Kanehira ◽

R. Takata ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Peripheral Blood ◽

Renal Cell ◽

Inflammatory Markers ◽

Advanced Renal Cell Carcinoma

Download Full-text